[
    [
        {
            "time": "",
            "original_text": "【银河医药孟令伟/刘晖】公司点评丨天坛生物 (600161)：业绩符合预期，看好发展前景",
            "features": {
                "keywords": [
                    "天坛生物",
                    "业绩",
                    "符合预期",
                    "发展前景"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【银河医药孟令伟/刘晖】公司点评丨天坛生物 (600161)：业绩符合预期，看好发展前景",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]